Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


25.08.2025

1 Am J Pathol
9 BJU Int
1 BMC Cancer
1 Br J Radiol
1 Cancer
2 Cancer Imaging
2 Cancer Res
1 Cancer Treat Res
1 Clin Imaging
2 Eur J Radiol
2 Eur Radiol
3 Eur Urol
2 Int J Radiat Oncol Biol Phys
4 Int J Urol
4 N Engl J Med
1 Oncogene
4 Prostate
1 Radiol Imaging Cancer
1 Urol Int
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. GREIG A, Henrique R, Xie B, Thrasivoulou C, et al
    Super-Resolution Microscopy Reveals Alterations in Clathrin Structure in Human Cancer Tissue.
    Am J Pathol. 2025;195:1619-1626.
    PubMed         Abstract available


    BJU Int

  2. CHONG B, Chen K
    Reply to 'A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer' by Su et al.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16898.
    PubMed        

  3. CHIAM K, Bang A, Nair-Shalliker V, Caruana M, et al
    Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16896.
    PubMed         Abstract available

  4. ITO K, Mori K, Kumar R, Sabnis RB, et al
    Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia.
    BJU Int. 2025 Aug 24. doi: 10.1111/bju.16900.
    PubMed         Abstract available

  5. SU PJ, Shao IH, Lin YH
    A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16897.
    PubMed        

  6. FLETCHER SA, Macura KJ, Pavlovich CP
    Author response to comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 17. doi: 10.1111/bju.16869.
    PubMed        

  7. COLLINS KK, Virdee PS, Roberts N, Oke JL, et al
    Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.
    BJU Int. 2025;136:372-384.
    PubMed         Abstract available

  8. BERRENS AC, Buckle T, van Oosterom MN, Slof LJ, et al
    Renal clearance of fluorescent agents can compromise image-guided surgery along the urinary tract.
    BJU Int. 2025;136:515-522.
    PubMed         Abstract available

  9. LENI R, Tin AL, Liso N, Carlsson SV, et al
    Magnetic resonance imaging for long-term active surveillance biopsy decision-making.
    BJU Int. 2025;136:500-506.
    PubMed         Abstract available

  10. LEPOR H, Persily J, Parry S, Rapoport E, et al
    Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
    BJU Int. 2025;136:447-451.
    PubMed         Abstract available


    BMC Cancer

  11. DENG S, Huang D, Han X, Zhang H, et al
    A novel MRI-based habitat analysis and deep learning for predicting perineural invasion in prostate cancer: a two-center study.
    BMC Cancer. 2025;25:1367.
    PubMed         Abstract available


    Br J Radiol

  12. HE CL, Yang T, Zhang MN, Yao J, et al
    A Novel Approach to Differentiate Prostate Cancer from Prostatitis in the Peripheral Zone.
    Br J Radiol. 2025 Aug 20:tqaf186. doi: 10.1093.
    PubMed         Abstract available


    Cancer

  13. FALAGARIO UG, Pellegrino F, Abbadi A, Bjornebo L, et al
    Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.
    Cancer. 2025;131:e70045.
    PubMed         Abstract available


    Cancer Imaging

  14. YAO F, Lin H, Xue YN, Zhuang YD, et al
    Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT.
    Cancer Imaging. 2025;25:103.
    PubMed         Abstract available

  15. A GLEMSER P, Netzer N, H Ziener C, Wilhelm M, et al
    Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence.
    Cancer Imaging. 2025;25:102.
    PubMed         Abstract available


    Cancer Res

  16. VENKADAKRISHNAN VB, Presser A, Voss NCE, Neiswender J, et al
    Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression.
    Cancer Res. 2025 Aug 21. doi: 10.1158/0008-5472.CAN-25-0636.
    PubMed         Abstract available

  17. HOSSEINI N, Mannan R, Rebernick RJ, Su F, et al
    Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration Resistant Prostate Cancer.
    Cancer Res. 2025 Aug 18. doi: 10.1158/0008-5472.CAN-24-3687.
    PubMed         Abstract available


    Cancer Treat Res

  18. SINGHAL G, Garg P, Mohanty A, Kollimuttathuillam SV, et al
    Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy.
    Cancer Treat Res. 2025;129:267-291.
    PubMed         Abstract available


    Clin Imaging

  19. CHIMMULA RR, Green M, Tann M, Koch M, et al
    Comparative analysis of machine learning-derived nomogram and biomarkers in predicting side-specific extraprostatic extension: Preliminary findings.
    Clin Imaging. 2025;125:110556.
    PubMed         Abstract available


    Eur J Radiol

  20. AGROTIS G, Woo S, Jaderling F, Ursprung S, et al
    Radiological T-staging in prostate Cancer: Towards a universal MRI-based scoring system.
    Eur J Radiol. 2025;191:112363.
    PubMed         Abstract available

  21. ZHANG X, Shen H, Xu Q, Tu C, et al
    CT derived myocardial extracellular volume predict major adverse cardiovascular events in patients with prostate cancer.
    Eur J Radiol. 2025;192:112371.
    PubMed         Abstract available


    Eur Radiol

  22. SYER T, Carmo B, Sanmugalingam N, Lawson B, et al
    On-table monitoring of prostate MRI could enable tailored utilisation of gadolinium contrast.
    Eur Radiol. 2025;35:5701-5709.
    PubMed         Abstract available

  23. AGROTIS G, Ursprung S, Schoots IG
    Personalised prostate MRI: tailoring contrast medium use in an era of increasing demand.
    Eur Radiol. 2025;35:5710-5713.
    PubMed         Abstract available


    Eur Urol

  24. LIN PH, Burwell AD, Giovannucci EL, Loeb S, et al
    Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
    Eur Urol. 2025 Aug 19:S0302-2838(25)00433-6. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available

  25. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
    Re: Prostate Cancer: A Review.
    Eur Urol. 2025 Aug 19:S0302-2838(25)00437-3. doi: 10.1016/j.eururo.2025.
    PubMed        

  26. DEMOGEOT N, Sargos P, Salleron J, Guerif S, et al
    Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.
    Eur Urol. 2025 Aug 14:S0302-2838(25)00436-1. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  27. ONG WL, Davidson M, Wronski M, Kang T, et al
    Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Aug 15:S0360-3016(25)06145.
    PubMed         Abstract available

  28. SONG Y, Dornisch AM, Dess RT, Margolis DJA, et al
    Multidisciplinary Consensus Prostate Contours on Magnetic Resonance Imaging: Educational Atlas and Reference Standard for Artificial Intelligence Benchmarking.
    Int J Radiat Oncol Biol Phys. 2025;123:183-194.
    PubMed         Abstract available


    Int J Urol

  29. YAMAMOTO Y, Fujimoto S, Hashimoto M, Minami T, et al
    Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70202.
    PubMed         Abstract available

  30. SHIMOMURA T
    Editorial Comment to "Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study".
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70185.
    PubMed        

  31. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70197.
    PubMed         Abstract available

  32. ARAI S
    Editorial Comment on Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis.
    Int J Urol. 2025 Aug 21. doi: 10.1111/iju.70208.
    PubMed        


    N Engl J Med

  33. EKLUND M, Thompson IM Jr, Cooperberg MR
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831.
    PubMed        

  34. SU CY, Hasebe M
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831.
    PubMed        

  35. GREEN HD, Jackson L, Bailey SER
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831-832.
    PubMed        

  36. BANCROFT EK, McHugh JK, Eeles RA
    Screening for Prostate Cancer with a Polygenic Risk Score. Reply.
    N Engl J Med. 2025;393:832.
    PubMed        


    Oncogene

  37. TONG T, Lei H, Huang M, Yang Z, et al
    HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03548.
    PubMed         Abstract available


    Prostate

  38. THILLAINADESAN G, Amemiya Y, Nam R, Seth A, et al
    Machine Learning Approach Identifies miRNA Biomarkers for Post Surgical Patient Stratification in Prostate Cancer.
    Prostate. 2025 Aug 16. doi: 10.1002/pros.70034.
    PubMed         Abstract available

  39. XU K, Khan A, Evancho P, Chu M, et al
    Analysis of the Increased Incidence of Aggressive Prostate Cancer After Prior Testicular Cancer.
    Prostate. 2025 Aug 16. doi: 10.1002/pros.70035.
    PubMed         Abstract available

  40. PAVLOVICH CP, Wei J, Gielzak M, Shi Z, et al
    Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.
    Prostate. 2025 Aug 18. doi: 10.1002/pros.70037.
    PubMed         Abstract available

  41. KURUCZ LM, Natali T, Westerhout S, Hagens M, et al
    Prostate Volume and PSA-Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics.
    Prostate. 2025 Aug 18. doi: 10.1002/pros.70036.
    PubMed         Abstract available


    Radiol Imaging Cancer

  42. RODRIGUES AC, de Almeida JG, Rodrigues N, Moreno R, et al
    Improving Clinically Significant Prostate Cancer Detection with a Multimodal Machine Learning Approach: A Large-Scale Multicenter Study.
    Radiol Imaging Cancer. 2025;7:e240507.
    PubMed         Abstract available


    Urol Int

  43. LUO H, Liao G, Liu Y
    Efficacy of Neoadjuvant Hormone Therapy Combined with Radical Prostatectomy in Improving Oncological Outcomes for Patients with cT3 Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2025 Aug 13:1-37. doi: 10.1159/000547875.
    PubMed         Abstract available


    Urology

  44. GARNICK MB, Kent MA
    Editorial Comment on "Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Nonbinary Patients: Retrospective Review of a Single-Institution Experience".
    Urology. 2025 Aug 22:S0090-4295(25)00804-0. doi: 10.1016/j.urology.2025.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.